新型PET显像剂<sup>18</sup>F-FACBC在前列腺癌中的应用进展

高骏; 段玉清; 于江; 李祎亮; 高骏; 段玉清; 于江; 李祎亮

doi:10.3760/cma.j.issn.1673-4114.2017.04.010

[1]

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387.

[2]

Simsir A, Cal C, Mammadov R, et al. Biochemical recurrence after radical prostatectomy:is the disease or the surgeon to blame?[J]. Inter Braz J Urol, 2011, 37(3):328-335. DOI:10.1590/S1677-55382011000300006.

[3]

Avril N, Dambha F, Murray I, et al. The clinical advances of fluo-rine-2-D-deoxyglucose-positron emission tomography/computed tomography in urological cancers[J]. Int J Urol, 2010, 17(6):501-511. DOI:10.1111/j.1442-2042.2010.02509.x.

[4]

Lindenberg L, Choyke P, Dahut W. Prostate cancer imaging with novel PET tracers[J]. Curr Urol Rep, 2016, 17(3):18. DOI:10.1007/s11934-016-0575-5.

[5]

Bauman G, Belhocine T, Kovacs M, et al. ¹⁸F-fluorocholine for prostate cancer imaging:a systematic review of the literature[J]. Prostate Cancer Prostatic Dis, 2012, 15(1):45-55. DOI:10.1038/pcan.2011.35.

[6]

Krause BJ, Souvatzoglou M, Treiber U. Imaging of prostate cancer with PET/CT and radioactively labeled choline derivates[J]. Urol Oncol, 2013, 31(4):427-435. doi: 10.1016/j.urolonc.2010.08.008

[7]

Roethke MC, Kuru TH, Afshar-Oromieh A, et al. Hybrid positron emission tomography-magnetic resonance imaging with Gallium 68 prostate-specific membrane antigen tracer:a next step for imaging of recurrent prostate cancer-preliminary results[J]. Eur Urol, 2013, 64(5):862-864. DOI:10.1016/j.eururo.2013.08.003.

[8]

Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18) F-choline-based PET/CT for the diagnosis of recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2014, 41(1):11-20. DOI:10.1007/s00259-013-2525-5.

[9]

Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68) Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2):197-209. DOI:10.1007/s00259-014-2949-6.

[10]

Eiber M, Maurer T, Souvatzoglou M, et al. Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy[J]. J Nucl Med, 2015, 56(5):668-674. DOI:10.2967/jnumed.115.154153.

[11]

Eiber M, Weirich G, Holzapfel K, et al. ⁶⁸Ga-PSMA HBED-CC PET/MRI in intermediate and high-risk prostate cancer improves the intraprostatic tumor localization compared to multiparametric Mr[J/OL]. J Nucl Med, 2016, 57(Suppl 2):28[2017-03-01]. http://jnm.snmjournals.org/content/57/supplement_2/28.short.

[12]

Maurer T, Gschwend JE, Rauscher I, et al. Diagnostic efficacy of (68) Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer[J]. J Urol, 2016, 195(5):1436-1443. DOI:10.1016/j.juro.2015.12.025.

[13]

Washburn LC, Sun TT, Byrd B, et al. 1-aminocyclobutane[¹¹C]car-boxylic acid, a potential tumor-seeking agent[J]. J Nucl Med, 1979, 20(10):1055-1061.

[14]

Shoup TM, Goodman MM. Synthesis of[F-18]-1-amino-3-fluorocy-clobutane-1-carboxylic acid (FACBC):A PET tracer for tumor delineation[J]. J Labelled Comp Radiopharm, 1999, 42(3):215-225.DOI:10.1002/(SICI)1099-1344(199903)42:3<215:AID-JLCR180>3.0.CO;2-0.

[15]

Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-¹⁸F-fluorocyclobu-tanecarboxylic acid in human prostate cancer[J]. J Nucl Med, 2011, 52(5):822-829. DOI:10.2967/jnumed.110.086074.

[16]

Oka S, Hattori R, Kurosaki F, et al. A preliminary study of anti-1-amino-3-¹⁸F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer[J]. J Nucl Med, 2007, 48(1):46-55.

[17]

Kairemo K, Rasulova N, Partanen K, et al. Preliminary clinical experience of trans-1-amino-3-(18) F-fluorocyclobutanecarboxylic acid (anti-(18) F-FACBC) PET/CT imaging in prostate cancer patients[J/OL]. Biomed Res Int, 2014:305182[2017-03-02]. https://www.hindawi.com/journals/bmri/2014/305182/. DOI:10.1155/2014/305182.

[18]

Schuster DM, Taleghani PA, Nieh PT, et al. Characterization of primary prostate carcinoma by anti-1-amino-2-[(18) F]-fluorocyclobu-tane-1-carboxylic acid (anti-3-[(18) F] FACBC) uptake[J]. Am J Nucl Med Mol Imaging, 2013, 3(1):85-96.

[19]

Sörensen J, Owenius R, Lax M, et al. Regional distribution and kinetics of[¹⁸F]fluciclovine (anti-[¹⁸F]FACBC), a tracer of amino acid transport, in subjects with primary prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2013, 40(3):394-402. DOI:10.1007/s00259-012-2291-9.

[20]

Turkbey B, Mena E, Shih J, et al. Localized prostate cancer detection with ¹⁸F FACBC PET/CT:comparison with Mr imaging and histopa-thologic analysis[J]. Radiology, 2014, 270(3):849-856. DOI:10.1148/radiol.13130240.

[21]

Nanni C, Schiavina R, Boschi S, et al. Comparison of ¹⁸F-FACBC and ¹¹C-choline PET/CT in patients with radically treated prostate cancer and biochemical relapse:preliminary results[J]. Eur J Nucl Med Mol Imaging, 2013, 40 Suppl 1:S11-17. DOI:10.1007/s00259-013-2373-3.

[22]

McConathy J, Voll RJ, Yu W, et al. Improved synthesis of anti-[¹⁸F]FACBC:improved preparation of labeling precursor and automated radiosynthesis[J]. Appl Radiat Isot, 2003, 58(6):657-666. doi: 10.1016/S0969-8043(03)00029-0

[23]

Chaly T, Dahl JR. Thin layer chromatographic detection of kryptofix 2.2.2 in the routine synthesis of[¹⁸F]2-fluoro-2-deoxy-D-glucose[J].Int J Rad Appl Instrum B, 1989, 16(4):385-387. DOI:10.1016/0883-2897(89)90105-0.

[24]

Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma[J]. J Nucl Med, 2007, 48(1):56-63. DOI:10.1007/s00259-008-0993-9.

[25]

Schuster DM, Savir-Baruch B, Nieh PT, et al. Detection of recurrent prostate carcinoma with anti-1-amino-3-¹⁸F-fluorocyclobutane-1-carboxylic acid PET/CT and ¹¹¹In-capromab pendetide SPECT/CT[J]. Radiology, 2011, 259(3):852-861. DOI:10.1148/radiol.11102023.

[26]

Shuster JR, Lance RS, Troyer DA. Molecular preservation by extraction and fixation, mPREF:a method for small molecule biomarker analysis and histology on exactly the same tissue[J]. BMC Clin Pathol, 2011, 11(1):14. DOI:10.1186/1472-6890-11-14.

[27]

Chillarón J, Estévez R, Mora C, et al. Obligatory amino acid exchange via systems bo, +-like and y+L-like. A tertiary active transport mechanism for renal reabsorption of cystine and dibasic amino acids[J]. J Biol Chem, 1996, 271(30):17761-17770. DOI:10.1074/jbc.271.30.17761.

[28]

Romeo E, Dave MH, Bacic D, et al. Luminal kidney and intestine SLC6 amino acid transporters of B⁰AT-cluster and their tissue distribution in Mus musculus[J]. Am J Physiol Renal Physiol, 2006, 290(2):F376-383. DOI:10.1152/ajprenal.00286.2005.

[29]

Bodoy S, Martín L, Zorzano A, et al. Identification of LAT4, a novel amino acid transporter with system L activity[J]. J Biol Chem, 2005, 280(12):12002-12011. DOI:10.1074/jbc.M408638200.

[30]

Park SY, Kim JK, Kim IJ, et al. Reabsorption of neutral amino acids mediated by amino acid transporter LAT2 and TAT1 in the basolateral membrane of proximal tubule[J]. Arch Pharm Res, 2005, 28(4):421-432. DOI:10.1007/BF02977671.

[31]

Kanagawa M, DoiY, Oka S, et al. Comparison of trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid (anti-[¹⁸F]FACBC) accumulation in lymph node prostate cancer metastasis and lymphadenitis in rats[J]. Nucl Med Biol, 2014, 41(7):545-551. DOI:10.1016/j.nucmedbio.2014.04.004.

[32]

Asano Y, Inoue Y, Ikeda Y, et al.Phase I clinical study of NMK36:a new PET tracer with the synthetic amino acid analogue anti-[¹⁸F]FACBC[J]. Ann Nucl Med, 2011, 25(6):414-418. DOI:10.1007/s12149-011-0477-z.

[33]

Inoue Y, Asano Y, Satoh T, et al. Phase Ⅱa clinical trial of trans-1-amino-3-(18) F-fluoro-cyclobutane carboxylic acid in metastatic prostate cancer[J]. Asia Ocean J Nucl Medi Biol, 2014, 2(2):87-94.

[34]

Nanni C, Schiavina R, Rubello D, et al. The detection of disease relapse after radical treatment for prostate cancer:is anti-3-¹⁸F-FACBC PET/CT a promising option?[J]. Nucl Med Commun, 2013, 34(9):831-833. DOI:10.1097/MNM.0b013e3283636eaf.

[35]

Tolvanen T, Yli-Kerttula T, Ujula T, et al. Biodistribution and radiation dosimetry of[¹¹C]choline:a comparison between rat and human data[J]. Eur J Nucl Med Mol Imaging, 2010, 37(5):874-883. DOI:10.1007/s00259-009-1346-z.

[36]

Inoue Y, Asano Y, Satoh T, et al. Phase Ⅱa clinical trial of trans-1-amino-3-¹⁸F-fluoro-cyclobutane carboxylic acid in metastatic prostate cancer[J]. Asia Ocean J Nucl Medi Biol, 2014, 2(2):87-94.

[37]

Ren J, Yuan L, Wen G, et al. The value of anti-1-amino-3-¹⁸F-fluo-rocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recur-rent prostate carcinoma:a meta-analysis[J]. Acta radiologica, 2015, 57(4):487-493. DOI:10.1177/0284185115581541.